Skip to main content

Table 1 Patients and Bisphosphonate Therapy Characteristics

From: Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws

Authors/Study

Gender

Age

Comorbidities

Medications (Years)

Marunick et al. [4] CS Patient 1

F

59

OST

STE + METX + AL (3)

Yarom et al. [6] RS

    

Patient 2

F

73

HTN

STE + METX + AL (7), infliximab

Patient 3

F

76

HTN + Arrhythmia + hypercholesterolemia

AL (1.5)

Malden & Pai [7] CS Patient 4

F

56

NO

STE + AL (1), leflunomide

Khamaisi et al. [8] RS Patient 5

F

73

DM

AL (> 0,5)

Marx et al. [9] CS

    

Patient6

F

NA

OST

STE + METX + AL (3.1)

Patient 7

F

NA

OST

STE + METX + AL (6.3)

Patient 8

F

NA

OST

STE + METX + AL (3.3)

Hamada [10] CR

    

Patient 9

F

68

OST

STE + RISE (4)

Barrow [11] CR

    

Patient 10

F

70

OST

STE + AL (< 3)

Junquera et al. [12] CS

    

Patient 12a/12b

M

73

NO

STE + METX + AL (3.8)

Mehanna et al. [13] CR

    

Patient 13

F

55

NO

STE + Leflunomide + oral BPs (1)

Favia et al. [14] CS

    

Patient 14a/14b

F

67

OST

STE + IBAN (1)

Kwon et al. [15] CR

    

Patient 15

F

71

OST + DM

STE + AL (3); OH

Sedghizadeh et al. [16] RS

    

Patient 16

F

63

OST + HTN

STE + chemotherapy + AL (3)

Lo et al. [17] RS

    

Patient 17

NA

NA

NO

oral BPs (4.8)

Patient 18

NA

NA

Hip Osteonecrosis

STE + oral BPs (2.6)

Shin et al. [18] CR

    

Patient 19

F

67

OST + HTN

AL (1) + HTN Drug

Park et al. [19] CS

    

Patient 20

F

68

OST

STE + AL (5)

Patient 21

F

69

OST + PLE + TB

STE + AL (10)

Patient 22

F

70

OST + HTN

STE + AL (6)

Manfredi et al. [20] CS

    

Patient 23

F

68

OST + DM + HTN

AL (4.25)

Patient 24

F

65

OST + HTN

AL (5)

Patient 25

F

79

OST

AL (4)

Patient 26

F

57

OST + DM + HTN

AL (> 3)

Conte-Neto et al. [21] CR

    

Patient 27

F

58

NO

AL (5)

Patient 28

F

68

OST

STE + METX + AL (7)

  1. CS Case series, RS Retrospective study, CR Case report, NA Not available
  2. OST Osteoporosis, HTN Hypertension, DM, Diabetes Mellitus, GU gastric ulcer, PLE Pleuritis, TB Tuberculosis, STE Steroids, MTX Methotrexate; AL Alendronate, RISE Risedronate, IBAN Ibandronate, OH oral hypoglycemiant